Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs Silicon Motion Technology Corporation American Depositary Shares (SIMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs Silicon Motion Technology Corporation American Depositary Shares — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $59.03 (market cap $25.18B), while Silicon Motion Technology Corporation American Depositary Shares trades at $220.06 (market cap $8.36B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 3× Silicon Motion Technology Corporation American Depositary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 6 Days and Silicon Motion Technology Corporation American Depositary Shares for 0 Days on average.
| RPRX | SIMO | |
|---|---|---|
Market Cap | $25.18B | $8.36B |
Volume | 3,399,248 | 663,682 |
Sector | Health | Technology |
52-Week High | $63.96 | $336.90 |
52-Week Low | $36.18 | $80.16 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $32.42B | $8.35B |
Dividend Yield | 1.66% | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royalty Pharma (RPRX) trades at $56.57, down 2.09% on the day, with a bullish technical signal and strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue and net income show steady growth, supported by a high gross profit margin of 89.38%. Analyst consensus is unanimously bullish with a $63.33 price target.
The outlook remains positive given earnings momentum and strategic capital deployment, though risks include biopharma policy shifts and reliance on partner drug performance. The stock offers exposure to a diversified portfolio of blockbuster drugs with minimal operational risk, but investors should monitor upcoming earnings and broader sector dynamics.
Silicon Motion (SIMO) trades at $246.63, down 0.13% on the day, with technical indicators showing neutral signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $2.43 versus $2.13, and revenue growth projected to reach $1.3B in 2026. Analyst sentiment remains overwhelmingly positive with 81% buy ratings and a consensus price target of $356.25, representing 44% upside potential from current levels.
The outlook for SIMO appears favorable given accelerating enterprise storage demand and AI infrastructure expansion. Key risks include semiconductor cycle volatility and competitive pressures in NAND controllers. With robust profitability metrics including 31.6% ROE and expanding margins, the stock offers growth exposure to the AI storage market, though investors should monitor execution on Q3 2026 earnings expectations of $3.3 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About Silicon Motion Technology Corporation American Depositary Shares
Silicon Motion Technology Corporation designs and develops NAND flash controllers for solid-state storage, with flagship SSD, eMMC, and UFS controller products, including its Ferri-branded automotive and industrial storage solutions, used by OEMs and NAND flash makers worldwide.
Read more on SIMO →
